TRADING UPDATES: Angle hails study find; Eqtec buys plant in France
20th Jul 2022 20:50
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - Stocks in London ended the week in the green after positive retail sales data from the US, easing fears over future US interest rate hikes. Read More
Angle PLC - Surrey, England-based medical diagnostics company - Raises GBP20.1 million via share placing, marginally above the GBP20.0 million it aimed for. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Angle PLC on Wednesday said it has secured further business with its "first large scale pharma services" customer. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Angle PLC - Surrey, England-based medical diagnostics company - Notes researchers at King's College London published data investigating the role of invasive cellular protrusion, known as invadopodia, activity in prostate cancer, and a potential role in the formation of circulating tumour cells. Researchers used Angle's Parsortix system's ability to isolate CTCs from the blood of prostate cancer patients. Parsortix system isolates CTCs in 94% of prostate cancer patients, showing some association with matrix degradation and invasive cellular protrusion formation. This may allow novel therapeutic development targeting the mechanisms of invadopodia and reducing metastatic spread of the cancer, it says. Read More
Angle PLC - Surrey, England-based medical diagnostics company - Establishes partnership with MidLantic Urology to evaluate the use of its Parasortix system in prostate cancer clinical studies. MidLantic is as an affiliate of special urology services provider Solaris, which has over 500 clinical urology providers across 179 locations in the US, with over 729,000 annual patients. Angle hopes the collaboration will "enable potential sales" to Solaris' patient base. The first study is expected to start in the third quarter of 2022, with results to be available in 2023. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
Angle PLC - Surrey, England-based medical diagnostics company - Receives approval from the US Food & Drug Administration for the use of its Parasortix system for use in metastatic breast cancer patients. Parasortix isolates circulating tumour cells from the blood which can aid in the diagnosis, characterisation and monitoring of cancer, and do so in a much less invasive fashion than traditional tissue biospy. Read More
(Alliance News) - Stocks in London ended mostly higher on Wednesday as market participants look ahead to the latest minutes from the US Federal Reserve at 1900 BST. Read More
Angle PLC - Surrey, England-based medical diagnostics company - Says Prostate Cancer UK has given a GBP750,000 grant for a clinical study at Barts Cancer Institute, Queen Mary University of London. The trial will follow 200 men with localised prostate cancer over five years, assessed using Angle's Parsortix system, in bid to see whether the cancer will eventually spread. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
Angle PLC - Surrey, England-based medical diagnostics company - Notes University of Maryland Marlene and Stewart Greenebaum NCI Comprehensive Cancer Institute has published results of work undertaken in preclinical models of triple-negative breast cancer. Findings show isolation of live circulating tumour cells from a simple blood draw, using Angle's Parsortix system, can provide rapid information on patient response to existing chemotherapy treatments that can target metastasis more effectively than tumour growth. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued this week and not separately reported by Alliance News: Read More
LONDON BROKER RATINGS: Jefferies cuts Berkeley, Barratt and Bellway Read More